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Background and objective: In the last decade, the number of publications that report on the use
of external beam radiotherapy and high-dose-rate brachytherapy (HDR-BRT) in the treat-
ment of recurrent head and neck cancer has increased, but no studies compare external
beam radiotherapy and HDR-BRT. The aim of this study was to evaluate and to compare the
efﬁcacy and toxicity of the three-dimensional conformal radiotherapy (3D-CRT) and HDR-
BRT in the treatment of recurrent head and neck cancer.
Material and methods: A total of 64 patients with head and neck cancer recurrence were
randomly assigned at a 1:1 ratio to receive either 3D-CRT (50 Gy/25 fractions) in the control
group or HDR-BRT (30 Gy/12 fraction) in the experimental group.
Results: The overall survival rate of patients treated with HDR-BRT at 1 and 2-years was
74% and 67%, respectively, compare to 3D-CRT group – 51% and 32%, respectively
(P = 0.002). Local control at 1- and 2-years in patients who received HDR-BRT was
77% and 63% compare with 47% and 25%, respectively, for the patients who received
the 3D-CRT (P < 0.001). Most patients developed mild to moderate acute mucositis and
dermatitis. In the 3D-CRT group, severe late toxicity was determined in 11 patients
(35.5%), and in the HDR-BRT group, in 1 patient (3.1%) (P = 0.001). There was no grade 5
toxicity.
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Conclusions: Following our results, we concluded that HDR-BRT is a more effective and safer
treatment approach for head and neck cancer recurrences than 3D-CRT.
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Despite advances in multidisciplinary treatment for head and
neck cancer after radical treatment, approximately 20–50% of
patients are diagnosed with locoregional recurrence during
the ﬁrst two years [1–4]. The main treatment for recurrent
disease is surgery, but it is possible only for 15–30% patients,
and the ﬁve-year overall survival rate is 16–36% [1–3,5–9]. The
possibilities for reirradiation with external beam radiotherapy
(EBRT) are limited by normal tissue complications [7,10–13]; in
cases of high-dose-rate brachytherapy (HDR-BRT), a high total
dose can be delivered directly to the tumour and rapid dose
fall-off above planning target volume (PTV) allows for sparing
of normal tissue [6,12–14]. The results of retrospective studies
presented in the literature, using repeated three-dimensional
radiotherapy (3D-CRT) for head and neck cancer recurrence,
according to a 2-year overall survival (OS), local control (LC)
and toxicity, are poor: OS was 15.2–42%, LC – 24–50%; the rate of
grade 3 and 4 late toxicity was 1.4–47%, the rate of grade 5
(lethal) late toxicity was 2–16.5% [10,15–17]. The results of
several phase II and retrospective studies related to the use of
the HDR-BRT for treatment of head-neck cancer patients are
published so far; fractionation regimes are being actively
discussed. In these studies, 3–4 Gy fractions up to 30–40 Gy
total dose are administered to treat the head and neck cancer
recurrence most often, and 2-year OS rate was 19–63%, LC – 67–
71%; rate of toxicity grade 3 and 4 was 8–22.2% [6,12,13,18].
There are discussions available regarding the possibility to
reduce the rate and grade of late toxicity through the use of
less than 3 Gy per fraction in HDR-BRT group while increasing
the total number of fractions. Although the number of
publications, presenting the results of repeated 3D-CRT and
results of HDR-BR when treating the head and neck cancer
recurrence, increased recently, the research comparing the
effectiveness and safety of treatment using the three-
dimensional radiotherapy and high-dose-rate brachytherapy
have been not accomplished yet so far.
The aim of this study was to evaluate and to compare the
efﬁcacy and toxicity of the 3D-CRT and HDR-BRT in the
treatment of recurrent head and neck cancer.
2. Material and methods
From October 1, 2008, to February 11, 2011, a prospective
single-institution study was conducted in the Hospital of
Lithuanian University of Health Sciences Kaunas Clinics.
Sixty-four patients with head and neck relapse were randomly
assigned in a 1:1 ratio to receive either 3D-CRT (50 Gy/25
fractions) in the control group or hypofractionated HDR-BRT(30 Gy/12 fractions) in the experimental group. Randomisation
was performed using a computer program. One patient in the
control group after randomisation was removed from analysis
due to myocardial infarction. The permission to conduct this
clinical study was obtained from the Kaunas Regional
Biomedical Research Committee (No. BE-2-15).
2.1. Patients
Before reirradiation, all patients were evaluated for eligibility
and the following selection criteria were applied: (1) histologi-
cally conﬁrmed head and neck squamous cell cancer relapse;
(2) locoregional relapse identiﬁed in an area that had been
irradiated during previous radiotherapy using a total dose of
≥50 Gy; (3) Karnofsky Performance Score ≥ 80; (4) no distant
metastases; and (5) no late grade 3 and 4 toxicity after the
primary radiotherapy. The patients' characteristics are pre-
sented in Table 1.
2.2. Three-dimensional conformal radiotherapy
methodology used to treat the control group patients
For patients' immobilisation, thermoplastic masks with ﬁve
ﬁxation points were used. A computed tomography (CT) scan
from the base of the skull, including the neck, with 3-mm slices
was used for three-dimensional (3D) treatment planning. The
gross tumour volume (GTV – the volume of tumour, identiﬁed
by clinical and radiological tests) was deﬁned in the 3D
planning system ‘‘Eclipse’’. The clinical tumour volume (CTV)
was obtained by adding 5-mm margins along all directions
around the GTV. To generate the PTV, a 3–5 mm isotropic
margin was added to the CTV. Organs at risk (OAR) (e.g., spinal
cord, mandible, carotid artery) were delineated. The total dose
was calculated at the isocenter, so that the PTV would be
covered by ≥95% of the prescribed dose, and the maximum
dose level would not exceed 107% of the prescribed dose. This
also ensured that the cumulative dose for the spinal cord
would not exceed 50 Gy. During this study, the total dose of
50 Gy per 25 fractions was prescribed to all of the patients by
administering 2-Gy single fractions (Fig. 1).
2.3. High-dose-rate brachytherapy methodology used to
treat the patients from the experimental group
When treating patients with recurrent locoregional head and
neck cancer, the principles of the Paris system are applied [19].
The loop technique was used to treat the local recurrences of
the oral cavity and oropharyngeal tumours. The closed-end
tube technique was used most often after the disease relapse
had been diagnosed at the regional lymph nodes of the neck, at
the sites of localised salivary gland cancer recurrence, or at the
Table 1 – Patients' characteristics in the control (3D-CRT)
and experimental (HDR-BRT) groups.
Characteristic 3D-CRT HDR-BRT P
Sex 0.414
Male 25 (80.6) 23 (71.9)
Female 6 (19.4) 9 (28.1)
Age, median (range),
years
59 (46–78) 59 (39–75) 0.904
<60 years 16 (51.6) 17 (53.1)
≥60 years 15 (48.4) 15 (46.9)
Tumour localisation 0.926
Oropharynx 7 (22.6) 6 (18.8)
Hypopharynx 3 (9.7) 2 (6.2)
Oral cavity 9 (29) 12 (37.5)
Cancer unknown
primary
1 (3.2) 1 (3.1)
Larynx 2 (6.5) 2 (6.2)
Parotid salivary
gland
1 (3.2) 1 (3.1)
Paranasal sinuses 6 (19.3) 6 (18.8)
Lip 2 (6.5) 2 (3.1)
Tumour degree of
differentiation
0.78
G1–2 22 (71) 24 (75)
G3–4 9 (29) 8 (25)
T 0.898
T1–2 15 (48.4) 16 (50)
T3–4 16 (51.6) 16 (50)
N 0.85
N0 7 (22.6) 9 (28.1)
N1–2 18 (58.1) 18 (56.2)
N3 6 (19.3) 5 (15.7)
Primary treatment 0.428
RT only 4 (12.9) 3 (9.4)
Surgery and RT 6 (19.3) 9 (28.1)
Surgery and
chemoradiation
8 (25.9) 13 (40.6)
Chemoradiation 13 (41.9) 7 (21.9)
Primary RT dose,
median (range), Gy
66 (50–70) 66 (50–70) 0.535
<60 Gy 12 (38.7) 10 (31.2)
≥60 Gy 19 (61.3) 22 (68.8)
Time to reirradiation,
median (range),
months
15.2 (6.8–22.1) 14.9 (3–26.1) 0.707
<15 months 15 (48.4) 17 (53.1)
≥15 months 16 (51.6) 15 (46.9)
Localisation of
recurrence
0.938
Oropharynx 5 (16.1) 5 (15.6)
Oral cavity 5 (16.1) 8 (25)
Parotid salivary
gland
1 (3.2) 1 (3.1)
Paranasal sinuses 6 (19.4) 5 (15.6)
Neck lymph nodes 14 (45.2) 13 (40.6)
Treatment 0.898
Surgery and RT 15 (48.4) 16 (50)
RT 16 (51.6) 16 (50)
PTV, median (range),
cm3
177.3 (94.6–277.4) 34.8 (8–107) 0.001
Values are number (percentage) unless otherwise indicated.
RT, radiotherapy; PTV, planning target volume.
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sinuses. In both techniques, the catheters were placed as near
as possible at 10- to 15-mm intervals with a security margin of
10 mm in all directions around the target.After the catheter implantation, all of the patients under-
went a CT scan, with a slice thickness of 2.5 mm. The CT study
was transferred to the 3D planning system Oncentra (Nucle-
tron, The Netherlands). The GTV was delineated as identiﬁed
by clinical and radiological tests. The CTV encompassed the
GTV and possible surrounding microscopic tumour margins,
and in most cases fell into the range of 5 mm; PTV did not differ
from the CTV; the OAR was delineated. Prescribed and
reported doses were speciﬁed by D90 as determined by
dose-volume histogram (DVH) (Fig. 2). Dose heterogeneity
was speciﬁed by V100 (the percentage of PTV receiving 100% of
the prescribed dose), V150 (the percentage of PTV receiving
150% of the prescribed dose), and V200 (the percentage of PTV
receiving 200% of the prescribed dose) [20]. In our study, the
mean values were as follows: D90 = 2.25 Gy (range, 1.9–2.5 Gy),
equivalent to 90.2% of the reference dose of 2.5 Gy,
V100 = 70.01% (range, 44.1–95.2%), V150 = 25.13% (range, 14–
40.7%), V200 = 12.1% (range, 8.74–21.2%). The mean values of
the homogeneity index and dose non-uniformity ratio were
estimated to be 0.62 (range, 0.54–0.76) and 0.3 (range, 0.23–0.4),
respectively. During this study, all patients received two daily
fractions of 2.5 Gy to a total dose of 30 Gy, with an interfrac-
tional interval of at least 6 h.
2.4. Statistical analysis
Statistical analysis was performed using the SPSS software
package (Statistical Package for Social Sciences 20 for
Windows). To assess the association of qualitative indications,
the chi-square x2 criterion was used. When testing the
statistical hypotheses, a signiﬁcance level of 95% (P < 0.05)
was selected. To determine and compare the effectiveness of
radiotherapy, the median survival, 1- and 2-year overall
survival (OS) and local control (LC) was assessed in both
groups of patients using the Kaplan–Meier method. Statistical
comparison between two groups was accomplished using the
log rank criterion. The acute and late toxicities were assessed
using RTOG/EORTC toxicity criteria [21,22].
3. Results
3.1. Overall survival
The median survival of patients treated with hypofractionated
HDR-BRT was 33.4 months, and the 1- and 2-year OS reached
74% and 67% (Table 3), respectively, compare to patients
treated with 3D-CRT the median survival was 11.9 months,
and the 1- and 2-year OS was 51% and 32% (Table 2),
respectively (hazard ratio [HR] = 0.4, 95% CI = 0.2–0.71;
P = 0.002) (Fig. 3).
First, we performed a univariate Cox analysis on the
relevant factors that may be prognostic: N stage, the dose of
ﬁrst radiation, the reirradiation volume, surgery before
reirradiation and the interval between primary irradiation
and reirradiation. Second, we performed a multivariable
analysis including those factors in which the signiﬁcance
level in the univariate analysis did not exceed 0.2. After
performing the multivariate Cox analysis, it was determined
that the factors associated with better OS in the control group
Fig. 1 – Conformal dose patterns for a patient with oropharyngeal recurrence cancer in axial (A), coronal (B) and sagittal (D)
views. Dose-volume histogram (C): yellow curve – spinal cord (mean dose 6.06 Gy, min dose – 0.18 Gy, max dose – 15.3 Gy);
red – PTV (mean dose 50.98 Gy, min dose – 44.5 Gy, max dose – 52.4 Gy); green – right parotid (mean dose 18 Gy, min dose –
1.03 Gy, max dose – 22.34 Gy); violet – left parotid (mean dose 28.51 Gy, min dose – 5.83 Gy, max dose – 51.24 Gy).
Fig. 2 – Treatment plan using loop technique of HDR-BRT for patient with tongue recurrent cancer (PTV – dotted red line).
Isodose distributions on an axial (A), coronal (B) and sagittal (C) image are shown. 3D reconstruction of brachytherapy
catheters and PTV (D).
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Table 2 – Published data on EBRT for recurrent head and neck cancer.
Study N Dose of
reirradiation
Chemotherapy Late toxicity
Grade 3–4
Outcomes/comments
Langendijk
et al. [24]
34 60–66 Gy – 24% – pharynx/oesophagus;
9% – mucous membrane
2-year OS – 28%
2-year LC – 27%
Popovtzer
et al. [25]
66 15–79.6 Gy
(median 68 Gy)
47 (71%)
platinum-based
29% 2-year OS – 40%
2-year LC – 27%
Janssen
et al. [27]
75 20–75 Gy
(median 46 Gy)
10 pts.-CP
10 pts.-CB + TX
4 pts.-CP + 5-FU
1 pts.-5-FU
1 pts.-GMT
7 pts.-CTX
1.4% 1-year OS – 41%
2-year OS – 23%
1-year LC – 35%
2-year LC – 24%
Present study 31 50 Gy – 35.5% 1-year OS – 51%
2-year OS – 32%
1-year LC – 47%
2-year LC – 25%
5-FU, 5-ﬂuorouracil; HX, Hydroxyurea; CP, cisplatin; CB, carboplatin; TX, taxan; CTX, cetuximab; GMT, gemcitabine; OS, overall survival; LC,
local control.
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interval between the ﬁrst course and reirradiation (≥15 months
vs. < 15 months, P = 0.016) and lesser PTV volume (<177.3 cm3
vs. ≥177.3 cm3, P = 0.025); in the experimental group (HDR-
BRT), those factors were: N0-1 stage (vs. N2-3 stage, P = 0.006) a
longer interval between the ﬁrst course and reirradiation (≥15
months vs. < 15 months, P = 0.013), a lesser PTV volume
(<34.8 cm3 vs. ≥34.8 cm3, P = 0.025), and postoperative reirra-
diation (surgery and reirradiation vs. reirradiation, P = 0.046).
3.2. Local control
The median local control in experimental group was 28.1
months, and the one- and two-year LC was 77 and 63%
(Table 3), respectively, compare to control group the median
local control was 10.3 months, and the 1- and 2-year LC was
47% and 25% (Table 2), respectively (HR = 0.34, 95% CI = 0.14–
0.7; P < 0.001) (Fig. 4).
After multivariate Cox analysis, it was determined that
the factors associated with better LC in the control group (3D-
RT) were: N0-1 stage (vs. N2-3 stage, P = 0.012), a longer interval
between ﬁrst course and reirradiation (≥15 months vs. < 15
months, P = 0.044), and lesser PTV volume (<177.3 cm3 vs.Fig. 3 – Overall survival of the experimental (HDR-BRT) and
control (3D-CRT) groups from reirradiation.≥177.3 cm3, P = 0.044); in the experimental group (HDR-BRT): a
larger dose of the primary radiotherapy (≥60 Gy vs. < 60 Gy,
P = 0.007), a longer interval between the ﬁrst course and
reirradiation (≥15 months vs. < 15 months, P = 0.033), a lesser
PTV volume (<34.8 cm3 vs. ≥34.8 cm3, P = 0.016), and postop-
erative reirradiation (surgery plus reirradiation vs. reirradia-
tion, P = 0.001).
3.3. Toxicity
Most patients developed mild-to-moderate acute mucositis
and dermatitis. There was no grade 5 toxicity. In the
experimental group, severe (grade 3 and 4) acute toxicity
was shown in 11 patients (34.4%). Similarly to the data of the
experimental group, the severe acute toxicity in control group
was observed in 17 patients (54.8%) (P = 0.102).
Severe late toxicity occurred signiﬁcantly less frequently in
the experimental group patients, in comparison to control
group patients: 3.1% (n = 1) and 35.5% (n = 11), respectively
(P = 0.001).
Osteoradionecrosis occurred in 1 patient (3.1%) in the HDR-
BRT group over 3.5 months after the brachytherapy and was
treated by surgery. In the 3D-CRT group, 1 patient (3.2%)
developed skin ulceration, 2 patients (6.4%) developed ﬁbrosisFig. 4 – Local control of the experimental (HDR-BRT) and
control (3D-CRT) groups from reirradiation.
Table 3 – Published data on HDR-BRT for recurrent head and neck cancer.
Study N EQD2
a (Gy)
(a/b = 10)
EQD2
a (Gy)
(a/b = 3)
Treatment Late toxicity
Grade 3–4
Outcomes/comments
Hepel et al. [12] 30 35.8 39.6 192Ir-HDR-BRT mean 34
Gy (range 18–48 Gy)
16% 1-year OS – 56%
2-year OS – 37%
1-year LC – 54%
2-year LC – 45%
Wiegand et al. [30] 12 32.5 36 192Ir-HDR-BRT 20–30 Gy NA 1-year OS – 41%
2-year OS – 18%
Narayana et al. [13] 30 (a) 38
(b) 46.7
(c) 69.3
(a) 39.2
(b) 56
(c) 74
(a) OP + 192Ir-HDR-BRT
34 Gy/(n = 18)
(b) 192Ir-HDR-BRT 40
Gy/(n = 9);
(c) EBRT 40–50 Gy +
192Ir-HDR-BRT 20
Gy/(n = 3)
13%
No grade
4 reactions
2-year OS – 63%
2-year LC – 71%
Schiefke et al. [18] 18 (a) 32.5
(b) 78.5
(a) 36
(b) 82
(a) OP + 192Ir-HDR-BRT,
median dose 30 Gy
(15–44.8 Gy)/(n = 10)
(b) OP + 192Ir-HDR-BRT,
median dose 30 Gy
(15–44.8 Gy) + EBRT,
median dose 45 Gy
(6–49.6 Gy)/(n = 8)
22.2% 2-year OS – 59.8%
2-year LC – 64.8%
Present study 32 31.3 33 (a) OP + 192Ir-HDR-BRT
30 Gy/(n = 16)
(b) 192Ir-HDR-BRT 30
Gy/(n = 16)
3.1% 1-year OS – 74%
2-year OS – 67%
1-year LC – 77%
2-year LC – 63%
OP, surgical treatment; 192Ir, iridium 192; HDR-BRT, high-dose-rate brachytherapy; EBRT, external beam radiotherapy; OS, overall survival; LC,
local control; NA, not available.
a EQD calculated according to mean or median of total HDR-BRT dose.
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dryness of mouth, 3 patients (9.6%) developed stricture of
pharynx, 1 (3.2%) developed severe oedema of the larynx, and 2
patients (6.4%) developed osteoradionecrosis.
4. Discussion
Surgical treatment and radiotherapy of head and neck tumours
increases the probability of chronic pain and the disruption of
main vital functions: speech, mastication, swallowing, respira-
tion, and social interaction. 3D-CRT prolongs the survival of
patients with diagnosed head and neck cancer; however, the
development of xerostomia, dysphagia, dysgeusia, and post-
radiation tooth decay reduces quality of life [23]. The compari-
son of results obtained during our investigation with results
from other studies is problematic due to several reasons:
 There are no completed clinical studies in which 3D-CRT
would be compared against HDR-BRT;
 Different criteria for patient inclusion into the study;
 In most cases, acute toxicity was not evaluated according to
RTOG/EORTC toxicity criteria, and late reactions were
evaluated according to modiﬁed RTOG/EORTC toxicity
criteria or using some other criteria.
In the literature, the results of retrospective studies have
been presented most often; in these studies, heterogeneous
patient groups have been analysed and different treatment
regimens have been applied (Table 2).Langendijk et al. accomplished a prospective phase II study,
during which 34 patients were reirradiated using 3D-CRT [24].
The mean interval between primary radiation and reirradia-
tion was 90 months (range 12–233 months). The results of this
study indicated that among patients who were treated for
locoregional recurrence and second primary cancer, there was
no statistically signiﬁcant difference determined when asses-
sing 2-year LC (14% and 35%, P = 0.75) and OS (medians 14.9 and
11.8 months, P = 0.49). We compared these parameters with
results from the control group (3D-RT) of our study. Despite the
shorter interval between primary radiotherapy and reirradia-
tion, the results achieved by a lower total dose were
equivalent. Similar to our research, in this study, mucositis
(mostly grade 2) was observed in all patients, although the rate
of grade 3 or greater late toxicity in the pharynx and
oesophagus was considerably higher compared with our
research results (24% vs. 9.7%) and the rate of toxicity in other
organs was similar.
Popovtzer et al. published results of a study that involved 66
patients treated for the nonresectable recurrent or second
primary squamous cell head and neck cancer [25]. Reirradiation
was implemented using 3D-R or IMRT techniques, and 47 (71%)
patients also received platinum-based chemotherapy. Popovtzer
et al. included patients in their study who were diagnosed with
nasopharynx cancer relapse. According to the literature data, the
results of nasopharynx cancer recurrence treatment are signiﬁ-
cantly better compared to the cancer recurrence treatment
results in other head and neck localisations (5-year LC reached
47–85%, OS 47–65%) [26]. In this study, a total dose higher than
68 Gy and concurrent chemotherapy did not improve LC, this
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research. A higher rate of acute and late toxicities in our study
could have been caused by the fact that Popovtzer et al. used
IMRT equipment and the time between primary radiotherapy
and reirradiation was longer.
A retrospective analysis was performed by Janssen et al.
[27]. A total of 75 patients were treated for head and neck
cancer recurrence. The median total dose of reirradiation was
46 Gy (range 20–75 Gy). The 2-year OS was 23%, and LC was
24%. Similar results of 2-year OS (32%) and LC (25%) were
obtained; however, the rates of acute and late toxicities
differed. The lower rate of complications could have been
because some patients were administered a lower total dose of
reirradiation, and the time between primary radiotherapy and
reirradiation was slightly longer.
After comparing the results of the control group from our
study (3D-RT) with the ﬁndings of other scientists, it is possible
to draw the following conclusions: the control group patients
were administered a sufﬁcient total dose of reirradiation
(50 Gy), and administering chemotherapy in combination with
reirradiation does not improve the overall survival or the
results of LC. Treatment toxicity was acceptable.
Up till now, there are insufﬁcient data in the literature
regarding applications of HDR-BRT during treatment of head
and neck cancer recurrences. In 2012, Yamazaki et al. surveyed
the signiﬁcance of HDR-BRT when treating head and neck
cancer; only ﬁve studies analysing the application of this
method in disease relapse treatment were included in this
survey [28]. A comparison of HDR-BRT results when treating
recurrent head and neck cancer is given in Table 3. To compare
the effectiveness and toxicity of treatments from these
studies, an equivalent to conventionally fractionated radio-
therapy dose formula (EQD2) was used, when a/b = 10 for
tumour and acute reactions and a/b = 3 for late reactions [29].
Hepel et al. published results of treatment involving 30
patients diagnosed with head and neck cancer recurrence who
were treated using 192I-HDR-BRT [12]. The mean total dose was
34 Gy (range 18–48 Gy), the mean implant volume was 85 cm3
(range 34–265 cm3). The 2-year OS was 37%, and LC was 67%;
moderate grade mucositis was observed in most of patients, late
grade 3 and 4 reactions were diagnosed in 5 patients (16%), and
grade 5 complications were not observed. Better OS and LC
outcomes in our study could be associated with smaller PTV
volume, although the EQD2 for tumours in our study was lower.
A lower rate of severe late complications was conditioned by
smaller PTV and lower EQD2 for late reactions.
Wiegand et al. treated 12 patients who were diagnosed with
recurrent squamous head and neck carcinoma [30]. Recurrent
cancer had been identiﬁed at the base of the tongue in eight
patients, in the ﬂoor of the mouth in three patients and in the
tonsillar region in 1 patient. During high-dose-rate brachyther-
apy, a total dose of 20–30 Gy had been delivered by administer-
ing daily fractions of 2–3 Gy per fraction. The median OS was 8.5
months, while 2-year OS was 18%. The different OS rates in
these studies could be due to the fact that our study included
patients who were diagnosed with recurrent cancer in other
locations, including the larynx, paranasal sinuses, salivary
glands, and lips, and a portion of patients received a combined
surgical and HDR-BRT treatment. The rates of toxicity were not
evaluated by Wiegand et al.Narayana et al. published results of treatment involving 30
patients diagnosed with recurrent head and neck cancer [13].
Eighteen patients had undergone surgery before HDR-BRT; they
then received a total dose of 34 Gy, with two daily fractions of
3.4 Gy. Nine patients had received a stand-alone HDR-BRT, with
total doses of 40 Gy and two daily fractions of 4 Gy. The 2-year OS
and LC in all study subjects were 63% and 71%, respectively.
Acute grade 3 and 4 complications were diagnosed in 4 patients,
the rate of grade 3 late toxicity was 13%, and no grade 4 and 5
toxicities were noted. Our study had a higher rate of acute
toxicity: acute reactions were diagnosed in 11 patients, but there
were less late grade 3 and 4 complications – 1 patient (3.1%) was
diagnosed with osteoradionecrosis, possibly due to a lower
single dose of 2.5 Gy. Considering the EQD2 for tumour and late
radiotherapy reactions, it can be stated that the fractionation
regimen using 2.5 Gy had the same effectiveness and caused
less severe late reactions.
Schiefke et al. used high-dose rate brachytherapy to treat 18
head and neck cancer patients: 5 patients were treated for
primary head and neck cancer, and 13 patients were treated for
disease recurrence [18]. All patients from this study received
surgical treatment, 8 patients received a concurrent 3D-CRT, and
seven patients received chemotherapy. The 2-year OS and LC in
patients treated for recurrent disease were 59.8% and 64.8%. The
rate of grade 3 orgreater late toxicity was 22.2%. The longer 2-year
overall survival and lower rate of severe toxicity in our study may
be associated with a lower EQD2 for tumours and late reactions.
Comparing the results of the HDR-BRT test group analysed in
our study with the ﬁndings of other authors, it can be concluded
that the fractionation regimen based on lower doses delivered to
patients included in our study (2.5 Gy per fraction, two daily
fractions to a total dose of 30 Gy) is an effective treatment
method; administering concurrent chemotherapy does not
improve the overall survival or local control results.
5. Conclusions
Following our results, we concluded that hypofractionated
high-dose-rate brachytherapy is a more effective and safer
treatment approach for head and neck cancer recurrences
than external beam radiotherapy. Concurrent chemoreirradia-
tion is not better than reirradiation alone.
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